The Hemochromatosis drugs in development market research report provides comprehensive information on the therapeutics under development for Hemochromatosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemochromatosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Hemochromatosis by nine companies/universities/institutes. The top development phase for Hemochromatosis is preclinical with four drugs in that stage. The Hemochromatosis pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hemochromatosis pipeline products market are: Sirnaomics, Silence Therapeutics and Vifor Pharma Management.
The key targets in the Hemochromatosis pipeline products market include Transmembrane Protease Serine 6, Iron, and Apolipoprotein C III.
The key mechanisms of action in the Hemochromatosis pipeline product include Transmembrane Protease Serine 6 Inhibitor with three drugs in Phase I. The Hemochromatosis pipeline products include two routes of administration with the top ROA being Oral and three key molecule types in the Hemochromatosis pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.
Hemochromatosis overview
Hemochromatosis is an iron disorder in which the body simply retains too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure, and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C, and history of diabetes, heart disease, or liver disease.
For a complete picture of Hemochromatosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
